Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Blood|August 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsDelphine Réa, Michael J Mauro, Carla Boquimpani, et al.
Nature Genetics|June 2, 2009
Lin28 promotes transformation and is associated with advanced human malignanciesSrinivas R Viswanathan, John T Powers, William Einhorn, et al.
Leukemia|January 30, 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLAndreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Blood|March 14, 2012
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsMargaret Nieborowska-Skorska, Piotr K Kopinski, Regina Ray, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Haematologica|September 23, 2017
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatmentSusan L Heatley, Teresa Sadras, Chung H Kok, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Blood|August 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsDelphine Réa, Michael J Mauro, Carla Boquimpani, et al.
Nature Genetics|June 2, 2009
Lin28 promotes transformation and is associated with advanced human malignanciesSrinivas R Viswanathan, John T Powers, William Einhorn, et al.
Leukemia|January 30, 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLAndreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Blood|March 14, 2012
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsMargaret Nieborowska-Skorska, Piotr K Kopinski, Regina Ray, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Haematologica|September 23, 2017
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatmentSusan L Heatley, Teresa Sadras, Chung H Kok, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Pageof 21